Prostate Cancer Nexus
Transcript: Neal Shore on the EMBARK trial
Neal Shore, MD, FACS
Interview recorded October 2025. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
- So similarly as the co-PI on the EMBARK trial, which we started 11 years ago, we presented here at ESMO the final overall survival analysis. And when we look at patients who have high-risk biochemical relapse as defined by a doubling time of less than or equal to nine months, who had previously undergone either prostatectomy or radiation primary or both.
Patients who received enzalutamide and LHRH clearly is superior to monotherapy LHRH. We demonstrated that in our original metastasis free survival analysis published in New England Journal two years ago. We presented today the final overall survival.
The hazard ratio was 0.595, which is really one of the best hazard ratios in a phase three OS analysis. The monotherapy enzalutamide, while not reaching statistical significance, is clearly trending towards a better survival compared to the monotherapy LHRH.
So we also published that simultaneously in the New England Journal of Medicine. So that was also an important highlight for me and my collaborators. It's always great, we had so many great collaborators.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event